02 April 2024

Scancell Holdings plc

("Scancell" or the "Company")

Scancell to Present at 2024 AACR Annual Meeting

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that Professor Lindy Durrant will be presenting at American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California on 5-10 April 2024.

Scancell will present data on its open-label Phase 2 SCOPE trial, investigating its cancer vaccine, SCIB1, in combination with checkpoint inhibitors (CPIs) in advanced melanoma. SCIB1 previously demonstrated an 85% response rate among 13 first-line advanced melanoma patients.

The AACR conference is an internationally recognized annual meeting, serving as a focal point of the cancer research community where the latest advances in the cancer space can be shared amongst world leading experts. Scancell is presenting as part of the 'Cancer Vaccines: Ready for Prime Time?' clinical trials symposium, covering progress from a number of innovative clinical stage cancer vaccines, including follow up data from the BioNTech mRNA vaccine.

Presentation Details:

Title: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial

Session: CTMS01 - Cancer Vaccines: Ready for Prime Time?

Session Date and Time: Sunday 7 April 2024, 3:50 PM - 4:00 PM PST

Location: Ballroom 20 AB - Upper Level - Convention Center

Published Abstract Number: CT024

Speaker: Professor Lindy Durrant, Chief Executive Officer and Chief Scientific Officer

Authors: H. Shaw, P. Patel, M. Payne, S. Kumar, M. Highley, K. Prasad, R. Board, C. Barlow, S. Danson, R. Miller, G. Goodhew, F. Master, L. Durrant

-ENDS-

About the SCOPE Phase 2 clinical trial

SCOPE is an open label, multicohort, multicentre, Phase 2 study of SCIB1 in patients with advanced unresectable melanoma receiving either nivolumab with ipilimumab or pembrolizumab. SCIB1 is a deoxyribonucleic acid (DNA) plasmid vaccine encoding two CD8 epitopes from the melanoma antigens tyrosinase-related protein-2 and glycoprotein 100 (gp100), plus two CD4 epitopes from gp100. The purpose of the study is to determine whether the addition of SCIB1 to standard of care CPIs can improve the objective response rate (ORR) of patients with advanced melanoma relative to the CPIs alone. The ORR is defined as the proportion of patients with a complete or partial response at any time after the start of treatment. During the first stage of the SCOPE trial reported here, patients received SCIB1 in combination with the best treatment currently available, namely the CPIs nivolumab and ipilimumab. The First Stage milestone was designed to demonstrate at least a 70% ORR with an 80% power i.e. at least 9/15 patients responding, assessed by radiological imaging. Further information relating to the clinical trial can be found on the Company's website at https://www.scancell.co.uk and at  https://classic.clinicaltrials.gov/ct2/show/NCT04079166

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/